Laurus Labs inks deal to buy majority stake in Richcore for Rs 247 crore

Laurus Labs will fund the acquisition from its internal accruals and this acquisition will be revenue and PAT accretive

Drug firm Laurus Labs on Wednesday said it has signed definitive agreements with the Eight Roads Ventures, VenturEast Proactive Fund and VenturEast Life Fund III to acquire 72.55 pc stake in biotech firm Richcore Lifesciences for a cash consideration of Rs 246.67 crore.

The acquisition marks the company's entry into the broader biologics and biotechnology segments, providing it access to its high growth areas, globally and in India, Laurus Labs said in a statement.

Following the successful closure of thetransaction, Richcore will be renamed as Laurus Bio Pvt Ltd, it added.

The current promoters of Richcore led bySubramani Ramachandrappa will continue as promoters and will be responsible for its management and operations,Laurus Labs said.

Laurus Labs will fund the acquisition from its internal accruals and this acquisition will be revenue and PAT accretive, it added.

"We are very excitedon this acquisition, as this gives us entry into the high barrier biotechnology segment. Laurus Labs will bring scale to Richcore' s operations and can become a major player in the biotech contract development and manufacturing organisation (CDMO) space," Laurus Labs CEO Satyanarayana Chava said.

This will also help the companyin becoming a leader in biocatalysis as Richcore brings significant expertise in enzyme developmentfor pharmaceutical and other industrial applications, he added.

"Leveraging the synergies arising from Laurus's experience and Richcore's innovation, we plan to build scale as we continue to serve our existing customers and enter new biotech segments," Richcore Lifesciences Pvt Ltd Chairman and MDSubramani Ramchandrappa said.

Shares of Laurus Labs closed at Rs285.05per scrip on BSE, down 1.62 per cent over previous close.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel